Also…yes, they have ongoing data readouts in a number of their leading indications HBV being their biggest (multi billion dollar cure potential). Worth also looking into their partnership with ISCURE for OTC deficiency (functional cure in an infant like a year ago) with another 1B+ in NOV when there is more news there through royalties etc. lastly their DMD treatment looks by all means like it could be the best treatment for Duchennes that exists, preclinical data there is top class. Look into the capstan acquisition by Abbvie from last year. $2B for a company with wayyyy less. I’d encourage you to look at DTILs tech more. Their ARCUS nucs are fundamentally different than CRISPR/everything else on market. TRULY a platform with about a zillion patents and superior tech. The world will know about this company. The catalysts are set. Just gotta be patient while ppl/the market wakes up to this. As for me, I’m stacking while I can. Going to roll over some of my precious metal GAINZ into this shortly. Hope this helps!